Close Menu


The firm will apply the proceeds primarily to its drug development efforts.

COLD-PCR preferentially amplifies segments of DNA that contain mutations, and is thereby able to increase the sensitivity of downstream mutation-detection methods by a factor of 10 to 100. Transgenomic believes it can increase the sensitivity of the approach even further in order to detect low-concentration mutations in the blood that could serve as early indicators of cancer.

The firm licensed exclusive rights to the technology for combined use with Sanger sequencing as well as for mitochondrial DNA analysis.

A drug deemed unsafe or ineffective in a large pharmaceutical firm's clinical program may turn out to be the lead product in a smaller personalized medicine company's pipeline using pharmacogenomics strategies, according to Michael Phillips, who, as the director of pharmacogenomics at Genome Quebec, is currently leading a PGx study for Pfizer's failed hypercholesterolemia drug torcetrapib.

Clinical Data sold non-core assets from its purchase of Avalon to Intrexon.

The company said the economic slowdown affected business, but the full-year results should improve.

Sales of the firm's Familion tests drove its revenues up to $3.7 million for the quarter.

Fourth-quarter R&D spending rose 140 percent to $12.8 million from $5.3 million for the same period in fiscal 2008. Clinical Data said that the increase was driven by Phase III confirmatory clinical and safety trials for vilazodone, the company's drug candidate for depression.

PGx & molecular Dx

The approximately $17 million acquisition, announced last week, will have "no impact" on Clinical Data's focus as a pharmacogenomics company, according to CEO Drew Fromkin.


A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.